Immunomodulation signature
Research type
Research Study
Full title
Immunomodulation signature profile consequent to focused ultrasound ablation
IRAS ID
164228
Contact name
Elena Rosca
Contact email
Sponsor organisation
Hull and East Yorkshire Hospitals NHS Trust
Duration of Study in the UK
1 years, 5 months, 27 days
Research summary
The purpose of this study is to determine if the body’s own immune response against tumours is activated during focused ultrasound (FUS) treatments. FUS is a novel non-invasive technique used to heat tissue to a point where cell death will occur (ablation). FUS has recently been shown to encourage infiltration of immune cells into the tumour microenvironment. It is hoped that once these immune cells enter the tumour environment, following FUS treatments, that they will destroy any remaining cancer cells. This project sets out to identify the immunological changes induced by FUS and to establish a set of clinical immune signature changes that occur as the result of FUS ablation. The results of this study will serve as an indicator of feasibility for future development of localized specific immune augmentation techniques that can complement FUS tumour ablation, such as thermoresponsive immunomodulating liposomes.
REC name
Wales REC 6
REC reference
14/WA/1176
Date of REC Opinion
1 Oct 2014
REC opinion
Favourable Opinion